Spy-fall: Trump imperils intelligence pact

Amidst a restructuring of US intelligence leadership under Donald Trump and potential disruptions to the Five Eyes alliance, China has surged to become the world's second-largest drug developer, offering Western pharmaceutical companies critical intellectual property to navigate an upcoming patent cliff. Concurrently, The Economist has launched a curated weekly film and television guide designed to highlight globally diverse, notable titles while explicitly advising against unworthy viewing, complementing its subscriber-only coverage of unique international social experiments. These developments collectively reshape intelligence security, biotech market dynamics, and cultural consumption within a rapidly evolving geopolitical landscape.